| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT04550338 Details | 2021-04-23 Interventional | 3 | 0 | Tranexamic Acid COVID-19 | With vaccination efforts ongoing, a feasibility survey indicated there would be inadequate
recruitment - | |||
| NCT03630367 Details | 2021-04-23 Interventional | 4 | 0 | Dexamethasone Premature Birth Respiratory Dis… Respiratory Dis… | Unavailability of the medication - | |||
| NCT02569801 2015-000106-19 Details | 2021-04-23 Interventional | 2 | 71 | Fulvestrant Breast Neoplasm… Breast Cancer | The Sponsor decided to halt the development of GDC-0810, but not due to any safety concerns. - | |||
| NCT01125293 Details | 2021-04-23 Interventional | 1/2 | [1 Refs] | 46 | Bortezomib Everolimus Rituximab Waldenstrom Mac… Waldenstrom's M… | Per protocol, Phase II is to be terminated early if a less than 5% of the Phase II participants
observe a Very Good Partial Response or Better in the first 23 participants enrolled to Phase
II. - | ||
| NCT02788019 Details | 2021-04-21 Interventional | 4 | 52 | Ropivacaine Pain, Postopera… Postoperative P… | Unable to complete the sample size needed for 80% power due to changes in surgical approach to
adductor block usage. - | |||
| NCT00924664 Details | 2021-04-21 Interventional | 2 | 849 | Tanezumab Back Pain Low Back Pain | See termination reason in detailed description. Due to FDA-imposed clinical hold, further study drug dosing stopped prematurely and study was terminated. Designation of outcomes as primary, secondary based on study team input as study did not specify them as primary or secondary. | |||
| NCT03487848 2017-003338-94 Details | 2021-04-20 Interventional | 2 | 5 | Sofosbuvir Hepatitis Hepatitis A Hepatitis C Hepatitis C, Ch… Hepatitis, Chro… Chronic Hepatit… | Business objectives have changed This study was terminated early by sponsor for reasons unrelated to safety. | |||
| NCT02634021 Details | 2021-04-20 Interventional | 4 | 0 | Dexmedetomidine Midazolam Knee Injuries | The investigator had no more scientific interest about this issue. - | |||
| NCT04838860 Details | 2021-04-19 Interventional | 2 | 22 | Siltuximab Castleman Disea… Idiopathic Mult… | Internal Company Decision - | |||
| NCT04711863 Details | 2021-04-19 Interventional | 2 | - | Fluvoxamine COVID-19 Coronavirus Inf… Severe Acute Re… Coronavirus Inf… Mild to Moderat… Severe Acute Re… | Closure of main community treatment center - | |||
| NCT04616586 Details | 2021-04-19 Interventional | 3 | 555 | Siltuximab Acute Lung Inju… Lung Diseases Respiratory Dis… Respiratory Dis… Respiratory Tra… Respiratory Tra… Syndrome Acute Respirato… Pneumonia Respiratory Tra… | The REMAP-CAP and RECOVERY substudy results appear to support the survival benefit of
tocilizumab in corticosteroid-treated or untreated patients with critically ill
COVID-19-associated ARDS. - | |||
| NCT01526408 Details | 2021-04-19 Interventional | 3 | 11 | Famciclovir Meniere Disease Meniere's Disea… | HRI no longer conducting research. - | |||
| NCT00742014 Details | 2021-04-19 Interventional | 3 | - | Sildenafil Citr… Hypertension Pulmonary Arter… | absorption of oral sildenafil not consistent - | |||
| NCT03959384 Details | 2021-04-15 Interventional | 3 | 9 | Poractant alfa Bronchiolitis Bronchiolitis, … | Due to COVID19 hospital admissions by patients with moderate-severe bronchiolitis have
drastically decreased from 02/2020 to date. Moreover, many centers that had initially joined
the study project had great difficulties in the activation phase - | |||
| NCT03419403 2017-003171-64 Details | 2021-04-14 Interventional | 3 | 40 | ABT-414 Ophthalmic Solu… Temozolomide Vasoconstrictor… Glioblastoma Glioblastoma Mu… | The study was terminated because clinical development of depatuxizumab mafodotin in
glioblastoma was stopped due to lack of survival benefit. - | |||
| NCT02117466 2013-002023-41 Details | 2021-04-14 Interventional | 1/2 | 85 | Cetuximab Colorectal Neop… Metastatic Colo… | Primary endpoint could no longer be reached. - | |||
| NCT02030015 Details | 2021-04-14 Interventional | 4 | [1 Refs] | 16 | Miglustat Gangliosidoses Gangliosidoses,… Gangliosidosis,… Sandhoff Diseas… Tay-Sachs Disea… GM1 Gangliosido… GM2 Gangliosido… | Efficacy - | ||
| NCT01438112 Details | 2021-04-14 Interventional | 2/3 | 22 | Gemcitabine Interferons Mitomycin Mitomycins Valrubicin Adenoviridae In… Carcinoma Carcinoma in Si… Carcinoma, Tran… Urinary Bladder… Bladder Cancer Carcinoma in Si… Transitional Ce… | Change in study design - | |||
| NCT00484718 Details | 2021-04-14 Interventional | 4 | 6 | Celecoxib Oxycodone Osteoarthritis Osteoarthritis,… | See termination reason in detailed description. No efficacy analysis were conducted, as this study was stopped due to a high screen failure rate before the planned enrollment required to carry out the pre-specified efficacy analysis. | |||
| NCT03452527 Details | 2021-04-13 Interventional | 2 | 15 | Aflibercept Immunoconjugate… Choroidal Neova… Macular Degener… Neovascularizat… Wet Macular Deg… | Business Reasons - |